Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Adhesion of Reformulated Scopolamine Patch
NCT02839135Phase 1Completed
- Sponsor
- GSK
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of scopolamine in motion sickness (2 arms), sponsored by GSK. Primary endpoints: Maximum plasma concentration, Area under the curve from time zero extrapolated to infinity and 5 more. Started May 2016; status: completed.
02
Drugs
scopolamine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT02839135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839135.